Phase 4 Open-Label Safety Study of GLP-1 Drug in Clinical Practice
Phase 4 post-marketing study evaluating GLP-1 drug safety and tolerability over 24 weeks provides important long-term real-world safety data beyond pivotal trials.
Quick Facts
What This Study Found
Phase 4 post-marketing study evaluating GLP-1 drug safety and tolerability over 24 weeks provides important long-term real-world safety data beyond pivotal trials.
Key Numbers
Participants had 4-14 migraine days per month. Treatment: rimegepant 75 mg once daily for 24 weeks.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Phase 4 post-marketing study evaluating GLP-1 drug safety and tolerability over 24 weeks provides im
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention.
- Published In:
- The journal of headache and pain, 27(1), 17 (2025)
- Authors:
- Antinew, Jeremias, Fountaine, Robert J(3), Loprinzo, Vittorio, Straghan, Esther, Dubrovin, Sergey, DeBesi, Patrizia, Vatakis, Nick, Fullerton, Terence
- Database ID:
- RPEP-09952
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
Phase 4 post-marketing study evaluating GLP-1 drug safety and tolerability over 24 weeks provides important long-term real-world safety data beyond pivotal trials.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09952APA
Antinew, Jeremias; Fountaine, Robert J; Loprinzo, Vittorio; Straghan, Esther; Dubrovin, Sergey; DeBesi, Patrizia; Vatakis, Nick; Fullerton, Terence. (2025). A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention.. The journal of headache and pain, 27(1), 17. https://doi.org/10.1186/s10194-025-02225-7
MLA
Antinew, Jeremias, et al. "A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention.." The journal of headache and pain, 2025. https://doi.org/10.1186/s10194-025-02225-7
RethinkPeptides
RethinkPeptides Research Database. "A phase 4, 24-week, open-label study to evaluate the safety ..." RPEP-09952. Retrieved from https://rethinkpeptides.com/research/antinew-2025-a-phase-4-24week
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.